Products - Obesity | Topic

Showing 8 products

Date | Title

Overweight and obesity management (QS212)
Product type:
Quality standard
Published:
5 August 2025
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
14 May 2026
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
19 August 2026
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
16 January 2026
Expected publication date:
10 February 2027
Orforglipron for managing overweight and obesity ID6516
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital technologies for multidisciplinary weight management
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC
Retatrutide for managing overweight and obesity [ID6644]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ID6611 Obesity, overweight - semaglutide (including review of TA875)
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC